Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E Brightling

Showing results (151-160 of 296) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|March 7, 2009
Mepolizumab and exacerbations of refractory eosinophilic asthmaPranabashis Haldar, Christopher E Brightling, Beverley Hargadon, et al.
The Journal of Allergy and Clinical Immunology|March 11, 2008
Increased sputum and bronchial biopsy IL-13 expression in severe asthmaShironjit K Saha, Mike A Berry, Deborah Parker, et al.
American Journal of Respiratory and Critical Care Medicine|March 27, 2012
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trialMona Bafadhel, Susan McKenna, Sarah Terry, et al.
The European Respiratory Journal|February 2, 2013
Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum of asthmaticsIne Kuipers, Renaud Louis, Maité Manise, et al.
The Lancet. Respiratory Medicine|September 27, 2020
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trialsChristopher E Brightling, Mina Gaga, Hiromasa Inoue, et al.
ERJ Open Research|March 9, 2023
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial designLucia De Prado Gomez, Ian Pavord, William Busse, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Journal of Breath Research|November 23, 2020
Volatile organic compounds in a headspace sampling system and asthmatics sputum samplesRosa Peltrini, Rebecca L Cordell, Wadah Ibrahim, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 27, 2019
Sputum <i>Streptococcus pneumoniae</i> is reduced in COPD following treatment with benralizumabLeena George, Adam Wright, Vijay Mistry, et al.
Pageof 30

Showing results (151-160 of 296) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|March 7, 2009
Mepolizumab and exacerbations of refractory eosinophilic asthmaPranabashis Haldar, Christopher E Brightling, Beverley Hargadon, et al.
The Journal of Allergy and Clinical Immunology|March 11, 2008
Increased sputum and bronchial biopsy IL-13 expression in severe asthmaShironjit K Saha, Mike A Berry, Deborah Parker, et al.
American Journal of Respiratory and Critical Care Medicine|March 27, 2012
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trialMona Bafadhel, Susan McKenna, Sarah Terry, et al.
The European Respiratory Journal|February 2, 2013
Increased glutaredoxin-1 and decreased protein S-glutathionylation in sputum of asthmaticsIne Kuipers, Renaud Louis, Maité Manise, et al.
The Lancet. Respiratory Medicine|September 27, 2020
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trialsChristopher E Brightling, Mina Gaga, Hiromasa Inoue, et al.
ERJ Open Research|March 9, 2023
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial designLucia De Prado Gomez, Ian Pavord, William Busse, et al.
The Lancet. Respiratory Medicine|May 10, 2021
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational studyP Jane McDowell, Sarah Diver, Freda Yang, et al.
The European Respiratory Journal|March 30, 2023
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyondJonathan Corren, Christopher E Brightling, Louis-Philippe Boulet, et al.
Journal of Breath Research|November 23, 2020
Volatile organic compounds in a headspace sampling system and asthmatics sputum samplesRosa Peltrini, Rebecca L Cordell, Wadah Ibrahim, et al.
International Journal of Chronic Obstructive Pulmonary Disease|June 27, 2019
Sputum <i>Streptococcus pneumoniae</i> is reduced in COPD following treatment with benralizumabLeena George, Adam Wright, Vijay Mistry, et al.
Pageof 30